The Arterez team led by Dr. J.B. Tunac can demonstrate a ‘root-cause’ correlative relationship between vascular diseases such as CVD, diabetes, arthritis and many others supported by our pre-clinical and clinical research as well as dozens of published studies just since 2017. More importantly, we believe our discoveries may be a profound scientific breakthrough that could lead to a new paradigm for the identification, characterization and treatment of CVD and other vascular pathophysiologies with good potential for curative and preventive outcomes.
Cardiovascular Disease (CVD) is the world’s leading chronic killer impacting more than one-third of the world’s population. Direct and indirect healthcare costs due to CVD is expected to grow to an estimated $1.5 trillion by 2030. Among the top 150 developing nations worldwide, CVD is the largest health risk and cost.
Arterez is a Michigan bio-sciences group that has ascertained vascular pathophysiologies share common, multi-factorial ‘root’ causes, including damage to the endothelial glycocalyx, inflammation and oxidation and therefore require a complex, targeted therapeutic approach to enable curative and preventive outcomes.
The company is pioneering a first-in-class, novel diagnostic and therapeutic platform including the Glycalyx Detritus Fingerprint™, a diagnostic technology for disease identification and classification and GlycoCardia™ for treatment monitoring as well as Embotricin™, a triple compound, small molecule, anti-thrombotic oral therapy targeting the primary root causes of CVD. It has proven to prevent formation of emboli (clots) involving plaque regression and restoration of the glycocalyx and proved non-toxic up to 20x the effective dose in animal models.
Arterez is currently conducting various translational animal studies utilizing 3 of Arterez’ 9 (patent issued) compounds in parallel to clinical studies with our patent pending 7-biomarkers of vascular disease, each clinically correlated to arterial plaque. Series A funding of $10 million dollars is required to complete biomarker algorithms and kit development, GLP scale-up manufacturing, CMC, formulation and stability, pre-IND, chronic toxicology, FDA IND and cGMP manufacturing.
First in-human proof of concept studies are expected to begin Q3-Q4 2022. GAP, risk and cost analysis, development and regulatory timeline, Gantt and capital requirements have been carefully mapped to meet clinical objectives.
Arterez, Inc. wholly-owns GlycoTrx, LLC (diagnostics) and ComboRx, LLC (therapeutics) for parallel product development while enabling flexibility.
Embotricin™ proved to prevent formation of emboli (clots) involving plaque regression and/or restoration of the endothelial glycocalyx and has demonstrated no toxicity up to 20x the effective dose in a 30-day tox study.
Dr. Tunac developed and synthesized 9 active compounds leading to the abbreviated factorial 3-drug combo design Embotricin™. Testing showed activity vs. other chronic diseases such as diabetes type 2 and arthritis. These will also be developed following successful first in human trial/s vs. CVD.
Two SBIR applications and research collaborations have been established.
$10M is needed to meet all requirements prior to clinical trial/s. An estimated $15M will then be required to complete first in-human trials and position the company for targeted acquisition and public offering designed to provide shareholder liquidity and fund future platform research and development.
First in-human studies for Embotricin™ and therapeutic aide GlycoCardia™ against CVD indication/s are expected to begin in Q3 or Q4 of 2022 both in the US and/or other countries to be determined as we progress.
We are happy to provide a non-confidential deck to qualified investors as well as access to our proprietary data-room upon executed mutual NDA.
In conclusion: The Arterez team led by Dr. J.B. Tunac can demonstrate a ‘root-cause’ correlative relationship between vascular diseases such as CVD, diabetes, arthritis and many others supported by our pre-clinical and clinical research as well as dozens of published studies just since 2017. More importantly, we believe our discoveries may be a profound scientific breakthrough that could lead to a new paradigm for the identification, characterization and treatment of CVD and other vascular pathophysiologies including curative and preventive outcomes.
1) Methods & compositions for reversing disruption of the glycocalyx, inflammation & oxidative damage,
2) Biomarkers of vascular disease,
3) Drug treatment & biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption,
4) International PCT methods & compositions filing
5) Thromboembolic animal model for CVD & inflammation (filing n process).
Arterez, Embotricin and GlycoGardia trademarks are approved with several others in process
Arterez (Draft) Publicatications
A) Endothelial Glycocalyx Biomarkers in Cardiovascular Disease
B) Curative and preventive treatment for cardiovascular disease (CVD)
C) Novel animal model for ventricular ejection fraction measured by MRI
Novel Technology Platform:
Diagnostic Biomarker Panels
Glycalyx Detritus Fingerprint™ technology –
Vascular disease identification & characterization
GlycoCardia™ therapeutic aide –
Designed to monitor therapeutic efficacy for therapies
targeting the endothelial glycocalyx and/or inflammation.
Anti-Thrombotic Oral Therapies
Embotricin™ triple compound oral therapy –
Targets endothelial glycocalyx repair and maintenance,
inflammation and oxidation
a. Drug Treatment and Biomarker Panel Targeted
to Diseases Due to Multifactorial Ontology of
b. Biomarkers of Vascular Disease
c. Methods and Compositions for Reversing
Disruption of the Glycocalyx, Inflammation and
d. (Draft) Animal Model for CVD and Inflammation
Embotricin™ IND/FDA indications:
Embotricin™ proof of concept/non-US indications:
Cardiovascular Artery Disease
GlycoCardia™ therapeutic aide
Biomarker kit and algorithm validation
DSK Biopharma – compound manufacturing
Henry Ford Health System – translational studies
Jackson Labs – thromboembolic animal model dev.
Christal Pharmatech – analysis, formulation, stability
Charles River Labs – toxicology studies
Utah State University – corona virus pollutant study
Clinical Network Svcs. – GAP analysis/AUS dev plan
Transhit-Bio – clinical bio-samples sourcing
Arbor Assays – ELISA serum & plasma studies
Dr. Dave Feichner – modeling, data analysis
Nucleus Network – clinical investigator (AUS)
4D BioNexus, Dr. Bonnie Weiner, GreenChem –
licensing, regulatory & IND/clinical strategy
Legal and Advisory:
Weaver Austin Villeneuve & Sampson LLP
Corporate filings, offering documentation
Garrett & Bachand PC
Corporate Advisory (AUS)
Dr. Josephino Tunac launched
Farmaceutix, LLC (FTX)
R&D for anti-embolic bio-
markers and compounds*
Rationally synthesized 9
3x combo proved to prevent
& reverse arterial plaques
New studies launched with
natural mouse, biomarkers
biomarker patents filed
Surrogate markers identified for
development/testing of compounds
Developed natural arterial
plaque mouse model
Combo drug proved non-toxic
up to 20x the effective dose
Engaged firm to assist with platform
development and funding
FTX continues testing & development
of additional intellectual properties
Patent filings amended, audit completed, development pathway established
Arterez launched, FTX IP
assigned, team developed
Website built, new IP filed &
issued, providers engaged
IRB studies, compounds to GLP, SBIR/Omnimus grants
ELISA & animal studies, GAP
analysis, plan updated, series A
Phase I healthy, limited 1B
studies vs CHD, HF & HTN
IP valuation, engage licensing
partner/s and/or suitors
Seed raise, biomarkers added,
ELISA & HFHS** studies engaged
Website built, new IP filed &
issued, providers engaged
Formulation, optimization, stability,
chronic toxicology, pre-IND
Series B, patient recruitment,
Australia submissions, IND/IRB filings
Complete co-dev, licensing or other
for diagnostic and therapy
Consider IPO to continue
Historical development of antibiotic targeting microorganisms leading to cure of infectious disease. An equivalent approach is to target endothelial glycocalyx to cure CVD by an antiembolic™ mechanism.